[1]邵景萍.HPV联合TCT检测在宫颈疾病筛查中的应用[J].医学信息,2022,35(10):168-170.[doi:10.3969/j.issn.1006-1959.2022.10.043]
　SHAO Jing-ping.Application of HPV Combined with TCT in Cervical Disease Screening[J].Medical Information,2022,35(10):168-170.[doi:10.3969/j.issn.1006-1959.2022.10.043]
点击复制

HPV联合TCT检测在宫颈疾病筛查中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年10期
页码:
168-170
栏目:
诊疗技术
出版日期:
2022-05-15

文章信息/Info

Title:
Application of HPV Combined with TCT in Cervical Disease Screening
文章编号:
1006-1959（2022）10-0168-03
作者:
邵景萍
（天津市蓟州区人民医院妇科，天津 301900）
Author(s):
SHAO Jing-ping
(Department of Gynecology,Tianjin Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
HPV; TCT; 宫颈疾病; 敏感度
Keywords:
HPV; TCT; Cervical disease; Sensitivity
分类号:
R711.74
DOI:
10.3969/j.issn.1006-1959.2022.10.043
文献标志码:
A
摘要:
目的 研究HPV联合TCT检测在宫颈疾病筛查中的应用价值。方法 选取2020年3月-2021年3月在我院进行宫颈疾病筛查的3160例患者为研究对象，均行人乳头瘤病毒（HPV）、薄层液基细胞学（TCT）以及HPV联合TCT检查，比较不同年龄段HPV分型阳性检出率；以病理活检为诊断标准，比较HPV、TCT及HPV联合TCT检查的诊断敏感度、特异度、准确性。结果 HPV分型阳性检出率为23.41%，35~44岁、45~54岁年龄段阳性率高于18~24岁、25~34岁及≥55岁年龄段（P＜0.05），45~54岁年龄段HPV 16、18型阳性率均高于其他年龄段（P＜0.05）；TCT检出高危HPV阳性率为41.49%，病理学检测阳性符合率为89.25%；HPV联合TCT检查的敏感度高于HPV、TCT检查，且HPV的敏感度高于TCT（P＜0.05）；HPV联合TCT检查的特异度高于TCT、HPV，但TCT与HPV的特异度比较，差异无统计学意义（P＞0.05）；HPV联合TCT检查的准确度高于TCT、HPV，但TCT的准确度高于HPV（P＜0.05）。结论 在宫颈疾病筛查中应用HPV联合TCT检查准确度、敏感度以及特异度均较高，可及早诊断宫颈疾病，为临床及时有效治疗提供参考依据。
Abstract:
Objective To study the application value of HPV combined with TCT in cervical disease screening.Methods A total of 3160 patients who underwent cervical disease screening in our hospital from March 2020 to March 2021 were selected as the subjects. All of them were examined by human papillomavirus (HPV), thin-layer liquid-based cytology (TCT) and HPV combined with TCT. The positive detection rate of HPV typing in different age groups was compared. The diagnostic sensitivity, specificity and accuracy of HPV, TCT and HPV combined with TCT were compared.Results The positive rate of HPV typing was 23.41%, the positive rates of 35-44 years old and 45-54 years old were higher than those of 18-24 years old, 25-34 years old and ≥55 years old (P<0.05), and the positive rates of HPV 16 and 18 in 45-54 age group were higher than those in other age groups (P<0.05). The positive rate of high-risk HPV detected by TCT was 41.49%, and the positive coincidence rate of pathological detection was 89.25%. The sensitivity of HPV combined with TCT was higher than that of HPV and TCT, and the sensitivity of HPV was higher than that of TCT (P<0.05). The specificity of HPV combined with TCT was higher than that of TCT and HPV, but the difference between TCT and HPV was not statistically significant (P>0.05). The accuracy of HPV combined with TCT was higher than that of TCT and HPV, but the accuracy of TCT was higher than that of HPV (P<0.05).Conclusion The accuracy, sensitivity and specificity of HPV combined with TCT in cervical disease screening are high, which can diagnose cervical disease early and provide reference for timely and effective treatment.

参考文献/References:

[1]黄慧伟,邓茜,辛青,等.TCT、高危型HPV、hTERC和Se联合检测筛查宫颈癌[J].预防医学,2019,31(10):1057-1060.[2]唐晓红.TCT与HPV联合检测对宫颈癌癌前病变筛查价值研究[J].中国现代医药杂志,2019,21(9):86-88.[3]齐梅英,魏辉.液基细胞学、人乳头瘤病毒检测联合阴道镜在宫颈癌筛查中的应用价值分析[J].包头医学,2019,43(3):13-14.[4]向睿,王静依,孟侠,等.不同严重程度宫颈组织学病变中宫颈HPV感染检出率及HPV和TCT在宫颈病变筛查中的价值[J].中国妇幼保健,2019,34(18):4192-4194.[5]车洪智,马飞,付玉荣,等. 探讨模式液基薄层细胞学检测（TCT）技术和高危型HPV-DNA 检测与宫颈病变的相关性[J].中国医学装备,2017,14(3):76-79.[6]尤小燕,王雅莉,刘文枝,等.高危型HPV 联合细胞学检测在宫颈癌及癌前病变筛查中临床意义[J].实用预防医学,2017,24(8):986-988.[7]王秋红,杜桂清,邓桂霞,等.HPV 分型联合TCT 检测及宫颈活检对宫颈癌癌前病变早期筛查的临床应用分析[J].北京医学,2016,38(1):72-73.[8]黄绪芬.宫颈癌筛查中液基薄层细胞检查及人乳头瘤病毒检测联合阴道镜的临床应用[J].山西医药杂志,2019,48(17):2128-2130.[9]朱晓华,张晓兰,卢锦,等.高危型人乳头状瘤病毒配合液基薄层细胞学检查在宫颈癌早期癌前病变筛查中的应用价值分析[J].中国卫生检验杂志,2019,29(12):1502-1505.[10]刘露,孟丽华,杨子焱,等.高危型人乳头瘤病毒联合液基薄层细胞学在宫颈癌筛查中的临床价值分析[J].中国妇幼保健,2019,34(17):3904-3907.[11]任建民.TCT联合HR-HPV检测在宫颈癌及癌前病变筛查中的临床意义[J].医学理论与实践,2019,32(15):2339-2342.[12]闫琼琼,王晓娟.TCT、HPV联合阴道镜在宫颈癌前病变筛查中的应用价值[J].实用癌症杂志,2019,34(7):1104-1106.[13]赵君,赵媛.液基细胞学与HPV 分型联合检测对早期宫颈癌的筛查意义[J].实用癌症杂志,2018,33(1):143-146.[14]刘敏,余倩.HPV 联合TCT 检测在宫颈疾病筛查中的应用[J].检验医学与临床,2017,16(1):10-12.[15]靳秀清.HPV 联合TCT 检测在宫颈疾病筛查中的应用探究[J].中西医结合心血管病杂志,2017(12):124-126.[16]孙茂春,康晓琳,等.HPV-DNA 联合TCT 检查对于诊断宫颈疾病的价值及其病理分型研究[J]. 中国妇幼健康研究,2016,27(5):647-649.[17]霍文婧,梁茂盛,韩存芝.人乳头瘤病毒联合薄层液基细胞检查在子宫颈疾病筛查中的应用[J].肿瘤研究与临床,2016,28(2):103-106.[18]赵容.细胞游离亚铁原卟琳在宫颈病变检测中的诊断价值探讨[D].石家庄:河北医科大学,2017.[19]左玲,李顺英,邓亭月.TCT联合高危型HPV检测在社区宫颈癌筛查中的应用价值[J].海南医学,2016,27(10):1628-1630.[20]吴秋珍,毛瑛玉,林茂华,等.Aptima HPV E6/E7 mRNA 16,18/45基因型检测技术在宫颈癌前病变和宫颈癌筛查中的应用价值[J]. 诊断病理学杂志,2021,28(3):202-206.

相似文献/References:

[1]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
　NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Medical Information,2018,31(10):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[2]邬素珍,许焕英.宫颈人乳头瘤病毒感染的免疫研究进展[J].医学信息,2018,31(19):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
　WU Su-zhen,XU Huan-ying.Progress in Immunization of Cervical Human Papillomavirus Infection[J].Medical Information,2018,31(10):33.[doi:10.3969/j.issn.1006-1959.2018.19.012]
[3]祝亚军.高危型HPV-DNA及TCT检测筛查宫颈癌及宫颈癌前病变的价值[J].医学信息,2019,32(22):157.[doi:10.3969/j.issn.1006-1959.2019.22.054]
　ZHU Ya-jun.The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions[J].Medical Information,2019,32(10):157.[doi:10.3969/j.issn.1006-1959.2019.22.054]
[4]刘琳琳,宫 正,杨海嵘,等.宫颈癌的诊治及预防研究[J].医学信息,2021,34(03):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
　LIU Lin-lin,GONG Zheng,YANG Hai-rong,et al.Research on Diagnosis,Treatment and Prevention of Cervical Cancer[J].Medical Information,2021,34(10):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
[5]刘洪波,祁晓莉,乔 星,等.HPV分型检测联合TCT检查在宫颈病变筛查中的应用[J].医学信息,2018,31(08):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
　LIU Hong-bo,QI Xiao-li,QIAO Xing,et al.Application of HPV Typing Test Combined with TCT Examination in Screening Cervical Lesions[J].Medical Information,2018,31(10):152.[doi:10.3969/j.issn.1006-1959.2018.08.053]
[6]朱 军,张振君.妇女宫颈病变筛查分析[J].医学信息,2019,32(01):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
　ZHU Jun,ZHANG Zhen-jun.Screening Analysis of Cervical Lesions in Women[J].Medical Information,2019,32(10):139.[doi:10.3969/j.issn.1006-1959.2019.01.043]
[7]李明明,赵 芳,张亚青.TCT、HPV联合阴道镜检测在早期宫颈癌及癌前病变筛查中的应用价值[J].医学信息,2023,36(13):103.[doi:10.3969/j.issn.1006-1959.2023.13.020]
　LI Ming-ming,ZHAO Fang,ZHANG Ya-qing.Application Value of TCT, HPV Combined with Colposcopy in the Screening of Early-stage Cervical Cancer and Precancerous Lesions[J].Medical Information,2023,36(10):103.[doi:10.3969/j.issn.1006-1959.2023.13.020]
[8]见永康,吴泽俊,庄雅丽.宫颈癌筛查联合阴道镜活检防治宫颈癌前病变的价值研究[J].医学信息,2023,36(16):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
　JIAN Yong-kang,WU Ze-jun,ZHUANG Ya-li.Study on the Value of Cervical Cancer Screening Combined with Colposcopy Biopsy in the Prevention and Treatment of Cervical Precancerous Lesions[J].Medical Information,2023,36(10):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
[9]王 意,李子珊,雷 雯,等.HPV E6/E7 mRNA检测对HPV16/18 DNA阳性患者的分流价值[J].医学信息,2024,37(18):57.[doi:10.3969/j.issn.1006-1959.2024.18.010]
　WANG Yi,LI Zi-shan,LEI Wen,et al.Shunt Value of HPV E6/E7 mRNA Detection in HPV16/18 DNA Positive Patients[J].Medical Information,2024,37(10):57.[doi:10.3969/j.issn.1006-1959.2024.18.010]

更新日期/Last Update: 1900-01-01